pegfilgrastim + plerixafor

Pegfilgrastim + plerixafor is a **combination regimen** used to mobilize hematopoietic stem and progenitor cells (HSPCs) into peripheral blood for collection prior to autologous transplantation, primarily in patients with non-Hodgkin lymphoma and multiple myeloma. **Pegfilgrastim** is a pegylated granulocyte colony-stimulating factor (G-CSF) that **stimulates neutrophil production** and mobilizes stem cells by acting as a long-acting G-CSF. **Plerixafor** is a **CXCR4 chemokine-receptor antagonist** that disrupts the binding of stromal cell-derived factor-1α (SDF-1α) to CXCR4, releasing stem cells from the bone marrow matrix into circulation. This combination allows for effective stem cell mobilization even in poor mobilizers, often requiring fewer injections than filgrastim-based protocols. This regimen is **not FDA-approved** with pegfilgrastim but is supported by published studies and used off-label. The regimens are typically administered via subcutaneous injection[1][3]. The developers and principal manufacturers are **Amgen** for pegfilgrastim and **Sanofi/Genzyme** for plerixafor[1][4].

Other names

pegylated filgrastim